Lisata Therapeutics Inc. (LSTA)
Lisata Therapeutics Statistics
Share Statistics
Lisata Therapeutics has 8.62M shares outstanding. The number of shares has increased by 3.76% in one year.
| Shares Outstanding | 8.62M |
| Shares Change (YoY) | 3.76% |
| Shares Change (QoQ) | 2.68% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.73M |
| Failed to Deliver (FTD) Shares | 540 |
| FTD / Avg. Volume | 2.11% |
Short Selling Information
The latest short interest is 33.75K, so 0.4% of the outstanding shares have been sold short.
| Short Interest | 33.75K |
| Short % of Shares Out | 0.4% |
| Short % of Float | 0.5% |
| Short Ratio (days to cover) | 3.82 |
Valuation Ratios
The PE ratio is -1.24 and the forward PE ratio is -2.35. Lisata Therapeutics's PEG ratio is 0.18.
| PE Ratio | -1.24 |
| Forward PE | -2.35 |
| PS Ratio | 24.82 |
| Forward PS | 0.4 |
| PB Ratio | 0.84 |
| P/FCF Ratio | -1.28 |
| PEG Ratio | 0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lisata Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.16, with a Debt / Equity ratio of 0.
| Current Ratio | 6.16 |
| Quick Ratio | 6.16 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $38.46K |
| Profits Per Employee | $-768.65K |
| Employee Count | 26 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -798K |
| Effective Tax Rate | 3.84% |
Stock Price Statistics
The stock price has increased by -14.61% in the last 52 weeks. The beta is 1, so Lisata Therapeutics's price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | -14.61% |
| 50-Day Moving Average | 2.3 |
| 200-Day Moving Average | 2.84 |
| Relative Strength Index (RSI) | 54.49 |
| Average Volume (20 Days) | 25.6K |
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of 1M and earned -19.98M in profits. Earnings per share was -2.4.
| Revenue | 1M |
| Gross Profit | 1M |
| Operating Income | -22.41M |
| Net Income | -19.98M |
| EBITDA | -22.23M |
| EBIT | -22.41M |
| Earnings Per Share (EPS) | -2.4 |
Balance Sheet
The company has 16.21M in cash and 137K in debt, giving a net cash position of 16.07M.
| Cash & Cash Equivalents | 16.21M |
| Total Debt | 137K |
| Net Cash | 16.07M |
| Retained Earnings | -548.07M |
| Total Assets | 35M |
| Working Capital | 28.96M |
Cash Flow
In the last 12 months, operating cash flow was -19.36M and capital expenditures 0, giving a free cash flow of -19.36M.
| Operating Cash Flow | -19.36M |
| Capital Expenditures | 0 |
| Free Cash Flow | -19.36M |
| FCF Per Share | -2.32 |
Margins
Gross margin is 100%, with operating and profit margins of -2240.9% and -1998.5%.
| Gross Margin | 100% |
| Operating Margin | -2240.9% |
| Pretax Margin | -2078.3% |
| Profit Margin | -1998.5% |
| EBITDA Margin | -2223.5% |
| EBIT Margin | -2240.9% |
| FCF Margin | -1935.6% |
Dividends & Yields
LSTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LSTA is $15, which is 557.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 557.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Sep 15, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Sep 15, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -20.94 |
| Piotroski F-Score | 3 |